[Synergistic effect of fibronection and basic fibroblast growth factor on osteoblast adhesion efficiency].
OBJECTIVE
To investigate effects of the basic fibroblast growth factor (bFGF) and fibronection (FN) on the osteoblast adhesion on the bio-derived bone.


METHODS
The third generation of the osteoblast was treated with bFGF 0. 1, 1, 10, and 100 ng/ml, respectively, and then was seeded in the bio-derived bone, which had been modified with FN 0.1, 1, 10, and 100 microg/ml, or Polylysine, respectively. The cell adhesion was measured by the MTT assay. The cell density and the cell appearance were observed by the scanning electron microscope. The above-mentioned procedures were repeated by an application of the GRGDS peptide.


RESULTS
Both FN and bFGF could enhance the osteoblast adhesion efficiency on the bio-derived bone (P < 0.05). However, the osteoblast adhesion efficiency could be significantly strengthened by a combined use of FN and bFGF. FN and bFGF had a significant synergistic effect in statistics (P < 0.01), but Polylysine and bFGF had no such synergistic effect (P > 0.05). The combined use of FN and bFGF had a better effect on the cell density and the cell appearance than either of them when observed with the scanning electron microscope. Adhesion efficiency generated by the combined use of FN and bFGF was significantly blocked by the application of the GRGDS peptide.


CONCLUSIONS
The combined use of FN and bFGF has a significant synergistic effect on the osteoblast adhesion efficiency on the bio-derived bone. This effect is probably mediated by the RGD-integrin alpha5beta1 pathway.
Feng
Li
L
Department of Orthopedics, First Affiliated Hospital of Nanjing Medical University, Nanjing Jiangsu, 210029, P. R. China. fengli19811010@163.com
Cao
Xiaojian
X
Ren
Yongxin
Y
D000818:Animals; D001672:Biocompatible Materials; D018786:Bone Substitutes / Q000737:chemistry; D002448:Cell Adhesion / Q000187:drug effects*; D002478:Cells, Cultured; D004357:Drug Synergism; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage / Q000494:pharmacology*; D005353:Fibronectins / Q000008:administration & dosage / Q000494:pharmacology*; D010006:Osteoblasts / Q000166:cytology* / Q000187:drug effects* / Q000648:ultrastructure; D010012:Osteogenesis / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D023822:Tissue Engineering
D001672:Biocompatible Materials; D018786:Bone Substitutes; D005353:Fibronectins; D016222:Fibroblast Growth Factor 2